Search
for

    Sort by

    Research 451–480 of 1000+

    1. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor 2004 · 408 citations
    2. Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition Cell Cycle · 2006 · 295 citations
    3. Anti-androgenic activities of Ganoderma lucidum Journal of Ethnopharmacology · 2005 · 70 citations
    4. Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum Food Chemistry · 2006 · 64 citations
    5. Herbs for Benign Prostatic Hyperplasia Annals of Pharmacotherapy · 2002 · 54 citations
    6. Corn silk extract improves benign prostatic hyperplasia in experimental rat model Nutrition Research and Practice · 2017 · 20 citations
    7. The beneficial effects of Pumpkin (<i>Cucurbita pepo</i>L.) seed oil for health condition of men Food Reviews International · 2018 · 15 citations
    8. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs Pharmacopsychiatry · 2015 · 15 citations
    9. Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors Assay and Drug Development Technologies · 2018 · 11 citations
    10. Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats Research and reports in urology · 2022 · 6 citations
    11. Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors Uro · 2021 · 6 citations
    12. Clinical use of 5α-reductase inhibitors Cambridge University Press eBooks · 2001 · 3 citations
    13. Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement Urology Annals · 2024 · 2 citations
    14. Effects of 5-alpha reductase inhibitors Current Opinion in Urology · 2018 · 2 citations
    15. Effect of finasteride on prostate-specific antigen Lancet Oncology · 2006 · 2 citations
    16. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese Human Genomics · 2024 · 1 citations
    17. The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being Current Sexual Health Reports · 2015 · 1 citations
    18. Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis International Neurourology Journal · 2025
    19. African Journal of Biomedical Research 2025
    20. Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice International Journal of Molecular Sciences · 2023
    21. UTILIZAÇÃO DE FINASTERIDA NO TRATAMENTO DA HIPERPLASIA PROSTÁTICA BENIGNA – RELATO DE CASO Enciclopédia Biosfera · 2023
    22. Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial The Journal of Urology · 2017
    23. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs Archivio italiano di urologia, andrologia · 2016
    24. IMPACT OF LOW DOSE FINASTERIDE FOR THE TREATMENT OF ANDROGENIC ALOPECIA ON SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN PARTICIPATED IN POPULATION-BASED SCREENING FOR PROSTATE CANCER The Journal of Urology · 2009
    25. Are PSA adjustments necessary for prostate cancer screening in men taking finasteride for hair loss? Nature Clinical Practice Urology · 2007
    26. Hepatoprotective and anti-hyperplastic effects of silver nanoparticles biosynthesised using aqueous extracts of <i>M. scaber</i> : Insights from acetaminophen and testosterone experimental models E3S Web of Conferences · 2026
    27. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review Therapeutics and Clinical Risk Management · 2009 · 33 citations
    28. A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia Drug safety · 1998 · 12 citations
    29. Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Experimental and Сlinical Urology · 2022 · 4 citations
    30. 5-alpha reductase inhibitors use in prostatic disease and beyond Translational Andrology and Urology · 2023